ReviewFrontiers in physiology2025
Advances in stem cell-based therapeutics for acute high-altitude illness: research progress and prospects.
Review in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Time-dependent effects of hypoxia on mitochondrial dynamics, dysfunction and apoptosis in C8-D1A astrocytes.Open life sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute high-altitude illness (AHAI), triggered by hypobaric hypoxia following rapid ascent to high elevations, induces complex pathophysiological responses that may be life-threatening. Recent advances in regenerative medicine have highlighted the therapeutic potential of stem cells in mitigating hypoxia-induced damage. Among them, Mesenchymal stem cells (MSCs), the most extensively investigated, exert therapeutic efficacy through immunomodulation, attenuation of oxidative stress, and enhancement of tissue repair mechanisms. Their paracrine signaling profile facilitates angiogenesis and stabilization of the hypoxic microenvironment. Neural stem cells (NSCs) exhibit robust proliferation and differentiation under hypoxic conditions, offering a novel avenue for the treatment of high-altitude cerebral pathology. Additionally, induced pluripotent stem cells (iPSCs), with their pluripotency and patient-specific derivation, present significant promise for personalized, cell-based interventions. Experimental studies demonstrate that these stem cell types modulate the hypoxic milieu via secretion of cytokines, remodeling of the immune microenvironment, and promotion of neovascularization. Nonetheless, several translational challenges persist, including suboptimal homing efficiency, potential immunogenicity, and uncertain long-term safety profiles in high-altitude settings. Future research should prioritize elucidation of stem cell behavior in hypobaric hypoxia, optimization of delivery systems, and establishment of standardized therapeutic protocols. Rigorous clinical validation through evidence-based approaches will be essential to substantiate safety and efficacy. With continued advances in stem cell biology and translational techniques, stem cell-based therapy is poised to emerge as a viable strategy for the prevention and management of AHAI, provided that its clinical deployment is underpinned by robust scientific evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.